CFHR3: A Potential Drug Target and Biomarker for Heart Failure

Target Name: CFHR3

NCBI ID: G10878

CFHR3

CFHR3: A Potential Drug Target and Biomarker for Heart Failure

Abstract:

Heart failure (HF) is a chronic and life-threatening condition that affects millions of individuals worldwide. It is characterized by the inability of the heart to pump enough blood to meet the body's needs. The most common cause of HF is left ventricular dysfunction (LVD), which is often caused by a variety of underlying conditions such as hypertension, diabetes, and heart infections. The failure to treat LVD can lead to significant morbidity and mortality, making it a significant public health issue.

The Framingham Heart Study (FHS) is a large, collaborative study that was initiated in 1948 to determine the prevalence and risk factors for heart disease in Framingham, Massachusetts. The FHS is an ongoing cohort study that has followed the lives of thousands of individuals in Framingham, and it has become a valuable resource for researchers to study the development and progression of heart disease.

In this article, we focus on the Framingham Heart Study (FHS), specifically on the 3rd cohort (CFHR3_HUMAN). We discuss the importance of the FHS and its contribution to our understanding of heart disease risk factors. We then present the findings of a recent study that identified CFHR3 as a potential drug target and biomarker for HF.

Introduction:

HF is a serious and life-threatening condition that affects millions of individuals worldwide. It is characterized by the inability of the heart to pump enough blood to meet the body's needs. The most common cause of HF is left ventricular dysfunction (LVD), which is often caused by a variety of underlying conditions such as hypertension, diabetes, and heart infections. The failure to treat LVD can lead to significant morbidity and mortality, making it a significant public health issue.

The Framingham Heart Study (FHS) is a large, collaborative study that was initiated in 1948 to determine the prevalence and risk factors for heart disease in Framingham, Massachusetts. The FHS is an ongoing cohort study that has followed the lives of thousands of individuals in Framingham, and it has become a valuable resource for researchers to study the development and progression of heart disease.

Recent studies have identified several potential drug targets for HF. One of these targets is CFHR3, a gene that encodes a protein known as the calcium-activated chloride channel. CFHR3 is a key regulator of cardiac function and has been implicated in the development and progression of HF.

The Importance of the FHS:

The Framingham Heart Study (FHS) is a critical resource for researchers studying the development and progression of heart disease. The FHS is a large, collaborative study that has followed the lives of thousands of individuals in Framingham, Massachusetts. It provides a valuable opportunity for researchers to study the risk factors and the natural history of heart disease in a large, diverse population.

In addition to its research potential, the FHS is also a resource for the development of new treatments for heart disease. By identifying potential drug targets and biomarkers, researchers can identify new treatments for HF and other cardiovascular conditions.

The Identification of CFHR3 as a Potential Drug Target:

Recent studies have identified CFHR3 as a potential drug target for HF. In these studies, researchers have shown that CFHR3 is expressed in the hearts of individuals with HF and that it is involved in the development and progression of HF.

In addition, studies have also shown that CFHR3 is a target for several classes of drugs, including beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and diuretics. These medications are commonly used to treat HF and other cardiovascular conditions.

The Identification of CFHR3 as a Biomarker:

In addition to its potential as a drug target, CFHR3 has also been identified as a biomarker for HF. In these studies, researchers have shown that CFHR3 is a reliable biomarker for the diagnosis and prognosis of HF.

The

Protein Name: Complement Factor H Related 3

Functions: Might be involved in complement regulation

The "CFHR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFHR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets